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Epidemiology of Ischaemic stroke epidemiology 
 
Cardiovascular diseases, particularly heart diseases and strokes, are the principal death cause for over 
17,5 milions of people in the whole world.  
The predominance of such cardiovascular diseases increases concerning a patient’s age, reaching 
measures between 4,61 and 7,33 for 100 inhabitants as for individuals older than 65 years old. [1] 
87% of most cases, stroke can present an ischaemic nature, whereas the remaining 13% show a 
haemorrhagic nature (10% intraparenchymal hemorrhage; 3% subarachnoid hemorrhage). [2]  
Stroke represents the second most common death cause in cardiovascular diseases with a death rate 
of 5,8 million dead people per year. Strokes are recognised as the fourth death’s life cause before 
myocardial infarction, tumors and serious respiratory conditions. 
The death life risk after an ischemic stroke is equivalent to 7% up to 7 days, 14% up to 30 days, 27% 
out of a year, and 53% out of 5 years, whereas the chances of experiencing a new cerebral ischemic 
episode, after a stroke, is of 2% up to 7 days, 4% up to 30 days, 12% up to one year and 29% up to 
five years. [3] 
According to some authors, there has been a reduction of a stroke’s incidence and prevalence, 
particularly as reported by Rothwell et al [4], between 1980 and 2002, the incidence of strokes was 
reduced by 40% in Great Britain. In a review carried out by Zhang et al [5], they revealed it’s 
impossible to confirm that there has been a reduction in the impact and predominance of cerebral 
ictus. Nonetheless, they found a decrease in terms of stroke death rates, due to an improvement in the 
treatment of strokes, both in the United States and in Europe. 
In the Western world, ischaemic stroke is the leading cause of disability, causing a heavy impact on 
the social and economic aspects of people’s lives.  
Evalueting patients over 65 years, in 50% they have hemiparesis, in 30% they can’t walk without 
support, in 19% they are aphasic and in 26% they live in assistance structure. [6] 
 
Physiopathology of the ischaemic stroke 
 
The risk factors of an ischaemic stroke are the same as those of atherosclerosis. Mainly, such factors 
can be divided into risk elements that be changeable and unchangeable. [7] 
Unchangeable risk factors include:  
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• Age: the risk of a stroke usually increases with age, particularly after 55 years of age, the 
risk tends to reduplicate. [8] 
• Sex: the risk of a stroke is higher in men than in women, with a man-woman ratio of 1,3:1 [9] 
• Genetic factors: patients who show familiarity with myocardial infarction (MI); TIA or 
stroke, have a risk that usually increases from 1,4 to 3,3 chances of having a stroke. [10]  
 
Changeable risk factors are: 
• Arterial hypertension: the risk reduction of a stroke is determined by an appropriate 
pharmacological antihypertensive therapy (PA <120/80) [11] 
• Diabetes mellitus: diabetic patients have a doubled risk of a stroke in comparison to individuals 
with standard glycaemic numbers [12] 
• Hypercholesterolemia: patients with inadequate control of cholesterol values, have a doubled 
risk of developing a stroke as compared to a subject with standard values. [13]  
• Smoking: it increases the risk of brain strokes from 2 to 4 times amongst patients who actively 
smoke, in relation to non-smoking patients. [13] [14] 
• Obesity and lack of physical activity  [15] [16] [17] 
 
The INTERSTROKE Study, published in 2010 and performed on 2337 patients from 22 countries of 
the world, reports that five risk factors, which represent the 80% of the global risk, are represented 
by arterial hypertension, smoking, obesity, diets and lack of physical activity. [18] 
Brain ischemia is caused by a drastic reduction or by an interruption of haematic supply to a cerebral 
territory that is more or less vast. Atherosclerotic carotid plaques can cause a TIA or a stroke through 
two pathogenetic mechanisms.  
Embolic Mechanism: embolism is nowadays considered the most frequent cause of transitory 
cerebral ischemia, which interests the vascularisation territory of the internal carotid. Embolism 
depends on the composition of the atherosclerotic lesion: the lipidic predominance is typical of 
unstable lesions, with more likelihood of ulceration and embolism. 
The primum movens of the arterial thromboembolism is the breakage of the overhead intima layer 
(cap) that determines erosions or deep ulcerations from which atheromasic or thrombotic material 
can detach in the hematic current, with a consecutive intracranial embolization, or it causes the 




Hemodynamic mechanism: it is due to a progressive increase of volume in the atheromatous 
plaque up to the serrated stenosis ( with a reduction of the arterial lumen>80%) or the extended 
thrombosis of a principal truncus arteriosus ( ICA or basilar artery) with a resulting reduction of the 
blood flow, peripheral ischemia, tissue hypoxia and ischemic stroke.  
The most frequent pathophysiologic mechanism (80-85% approximately) that pertains to the 
anterior circulation of carotid is the atheroembolic one.   
 
The Vulnerable Plaque and Atherosclerosis 
 
The term “vulnerable plaque” is used to define an unstable atherosclerotic plaque or a complex 
plaque. According to the classification of the American Heart Association, atherosclerotic lesions 
divide into six stages. The first stage is simbolised by isolated foamy cells, (called “lipidic point”). 
The second stage is characterised by “fatty streaks” and the third stage by intermediate lesions. 
Whereas in the fourth stage, we can observe the presence of atheroma; and in the fifth, there is 
fibroatheroma. Complex lesions represent the sixth stage, also including calcifications, breaks with 
resulting thrombosis, and embolisation of the plaque and intraplaque hemorrhage.   
Figure 1 Atherosclerotic plaque 
 
Vulnerable plaques are histologically described by a stringy thin cap and by a voluminous lipidic 
core. [19] [20] 
The identification of vulnerable carotid atherosclerotic plaques can be implemented through first level 
diagnostics investigations with supra-aortic trunks Eco-Color-Doppler (ECD), and through second 
level diagnostics (CT or MRI scan). The carotid ECD enables to quantify the stenosis degree and to 
accurately describe the macroscopic morphological characteristics of the carotid plaque (for example, 
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the fibrous cap). With the aid of ECD, the plaque’s composition can be examined.  Hypo-anaecogenic 
(lipid) and irregular plaques are often associated with cerebrovascular symptomatology as compared 
to hyperechogenic calcified plaques. [21] [22] 
As is common knowledge, since 1970, there has been a connection between histopathological 
characteristics of the atherosclerotic carotid plaque and the presence of cerebrovascular 
symptomatology. [23]  In 2006, Redgrave et al., published in the Oxford Plaque Study, a histological 
study regarding atherosclerotic carotid plaques acquired by patients exposed to carotid  
thromboendoarterectomy (CEA). 
Plaques were classified base on the presence of an inflammatory infiltrate and on their instability 
within the following groups: stable (a plaque that is mainly fibrous with an entire cap), predominantly 
stable (intraplaque inflammation and entire fibrous cap), unstable with an entire fibrous cap (thin cap 
and intact with voluminous lipid cap), unstable with a break in the fibrous cap.  
In this study, the majority of symptomatic patients' plaques presented a break of the fibrous cap 
(58,1%), intraplaque hemorrhage (64.4%), and a critical inflammatory infiltrate (66.8%). Even Gao 
et al. concluded that during their meta-analysis, ulcerated carotid plaques were unstable and 
significantly linked with neurological events. [20] 
The passage from a plaque defined as stable and a vulnerable one depends on a final balance between 
cellular migration/proliferation, production of the extracellular matrix, inflammatory infiltrate, 
(predominantly monocyte-macrophage and lymphocyte) and on the development of new vessels.  
The break of the fibrous cap is determined by an imbalance between forces that operate on the fibrous 
cap and on the resistance thereof. It would appear that all of the factors capable of reducing collagen’s 
synthesis from smooth muscle cells (for example, IFN-α) compromise the ability to repair and 
maintaining the cap intact. Macrophages present in the plaques can produce metalloproteinases 
(MMP) and elastolytic cathepsins responsible for the break of the collagen and the elastin of the extra-
cellular matrix. [24] 
The plaque’s vulnerability furthermore depends on the presence of new vessels, which appear fragile 
because they are composed of a single layer of endothelial cells. The new blood vessels can encounter 
a break with a consecutive intraplaque haemorrhage. Such heavy bleeding in some cases can 
determine the increase of the plaque’s volume and a subsequent rupture of the fibrous cap.   
Many studies dedicated to atherosclerotic coronary and carotid plaques have highlighted that the 
angiogenesis of a plaque can support the progression of plaques. In particular, it encourages the 
vulnerability and break of the plaque itself. Different factors contribute to angiogenesis, and they are 
caused by intraplaque inflammatory cells. New blood vessels express cohesion molecules such as E-
selectin and VCAM (vascular cell adhesion molecule-1), that summon lymphocyte T cells and 
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macrophages. Even the inflammatory infiltrate plays a crucial role in the gradual development and 
variability of the plaque. Taking the example of a study carried out by Moreno et al., they observed 
that during the break of an atherosclerotic coronary plaque, this fracture linked with the presence of 
an abundant inflammatory infiltrate. [25] 
The affiliation between inflammation and progression of the plaque is supported by inflammatory 
marker serums, such as the reactive protein C (PCR), serum amyloid A (SAA), IL6, IL18, TNFα, 
MMP2, and MMP9. [26] 
Notwithstanding the numerous investigation lead on atherosclerotic carotid and coronary plaques, the 
development mechanisms, progression, and break of the plaque remain disjointed. 
 
The development of the atherosclerotic plaque 
 
The accumulation of lipid in the vessel wall is the “primum movens” in the development of the 
atherosclerotic plaque, followed by the migration of multiple inflammatory cells which determine the 
formation and the accretion of the atherosclerotic plaque via a release of cytokine, that foster 
atherosclerosis.  
The pathogenetic theory that attempts to explain the atherosclerotic process is a cross-reaction, and 
it considers atherosclerosis as an inflammatory response of the vascular wall due to a damage of the 
endothelium. The inflammatory course plays a fundamental role in the pathogenesis of 
atherosclerosis.   
 
Figure 2 Cells in atherosclerotic plaque 
 
• CRONIC ENDOTHELIAL DAMAGE: inducted by endotoxins, hypoxia, hyperlipidemia, 
effects derived from smoking cigarettes, homocysteine, and hemodynamic factors. The 
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endothelial damage appears with an increase of permeability (loss from endothelial cells of 
intercellular binding and with the underlying connective). Such damage also displays an 
increment of adhesion molecules (ICAM-1, VICAM-1, E-selectin1, P-selectin2), the 
activation of endothelial pro-inflammatory and proatherogenic genes, from which derives the 
creation of cytokines and coagulation proteins.   
 
• EXTRA- CELLULAR LIPIDIC ACCUMULATION: 
 Lipo-protein particles accumulate in the tunica intima. These particles tie with proteoglycans 
of the extra-cellular matrix, and they form “fatty streaks.” The lipoproteins tethered to 
proteoglycans seem susceptible to oxidation and to other biochemical alterations, which 
facilitate the inflammatory process. In particular, lipoproteins go towards oxidation3 and a 
non-enzymatic glycosylation process4.  
As a result of these processes, it happens that the recruitment and the accumulation of 
leucocytes, which stick with the endothelium and for diapedesis between endothelial 
junctions, penetrate the intima where they start to absorb lipids, transforming into “foamy” 
cell. In such a process, monocytes neutrophils and T lymphocytes are principally involved. 
 
Figure 3 the formation of the plaque: a.  dysfunction of endothelial cell and their activation with the 
inflammatory stimulus, leukocyte cohesion and growth of endothelial permeability. b.  input of monocytes and 
transformation into macrophages and progressively into foam cells; sediment of the matrix and recall of 
smooth muscle cells. c. development of the necrotic heart and the fibrous cap; neovascularisation. d. erosion 
of the fibrous cap within unstable plaques and breakage of the plaque. 
7 
 
Leucocytes penetrate through the arterial wall thanks to chemotactic cytokines, amongst 
which chemotactic protein-1 for monocytes (MCP-1) produced by the endothelium as a 
response to oxidized lipoproteins. 
Atheromas also express a trio of selective chemokines for lymphocytes: the protein-10 
interferon-γ inducible (IP-10), the chemotactic factor α for T cells (I-TAC), and the monokine 
provoked by the interferon γ (MIG). The interferon γ present in atheromas plaques persuades 
the genes, which codify for this family of chemotactic cytokines for T cells.   
 
• ACCUMULATION OF LIPIDS AT A MONOCYTE LEVEL: it determines the development 
of a macrophage full of lipids (foam cells). Such a process is facilitated by a few molecules 
such as A scavenger receptor, CD36, and macrosialin. After that, foamy cells multiply under 
the influence of interleukin -3 and the factor, which encourages the growth of macrophages.  
  
• MIGRATION AND PROLIFERATION OF SMOOTH MUSCLE CELLS: these cells derive 
from tonaca media as a response to a platelet-derived growth factor (PDGF) caused by 
activated macrophages. Smooth muscle cells synthesize collagen, elastin, and glycoproteins 




• MINERALIZATION: plaques broaden calcification areas during their evolution. A few 
subsets of smooth muscle cells can foster the calcification through an increase of cytokines’ 
secretion, such as morphogenetic proteins of the bone.  
 
• ANGIOGENESIS: in the plaques, a dense vascular network, often occurs as a response to 
super angiogenic peptides expressed in the atheromas (VEGF-FGF, oncostatin M).  
 
The description of the presence of new blood vessels in the atherosclerotic carotid plaques 
was described initially in 1936. It was only at the beginning of the 1980s that scientific projects 







Lymphatic vessels within the atherosclerotic plaque 
 
Recently, investigations regarding atherosclerosis have pointed out the presence of lymphatic vessels 
inside the plaque.   
Lymphatic vessels are involved in different pathologies such as lymphedema, inflammation, 
autoimmune diseases, and tumors. Regardless of the presence of a complex physiopathology, 
literature about lymphatic vessels within atherosclerosis is insufficient. [27] 
In normal conditions, lymphatic vessels are made up of a dense network that extends itself inside the 
tissue, and often, they go with blood vessels, which are mainly venous. [28] Lymphatic vessels are 
founded on a single layer of endothelial cells, united with each other in a spasmodic way (button-like 
cell junction) and by unidirectional tubes. [29]  
In order to avoid their collapse, they are anchored to the extracellular matrix through strands.  
The origin of lymphatic vessels is controversial, taking two potential sources of lymphatic endothelial 
cells into consideration: blood vessels and mesenchymal cells. [30] During the embryogenesis, the 
development of lymphatic vessels begins after the stabilization of the advancement of blood vessels; 
especially, lymphatic vessels appear as if they originate from venous endothelial cells, that resettle in 
the neighboring tissue.  Prox1 stimulates such differentiation and migration. (fig.4) [31] [32] The 
bond between vascular endothelial growth factor C and D (VEGF-C e VEGF-D), and the receptor R-
3 (VEGFR-3) induces lymphogenesis, motivating proliferation, migration, and survival of lymphatic 
endothelial cells in vitro. [33] 
 
 
Figure 4 Development of lymphatic vasculature during embryogenesis. After the remodeling of the blood vasculature, lymphatic endothelial 




Recent studies concerning lymphatic vessels in inflammatory processes show how macrophages are 
involved in lymphogenesis, producing growth lymphogenic factors (i.e., VEGF-C e D). [34] [35] [36] 




       
Figure 5 Section of mammary artery, lymphatic vessels (D2-40) 
 
The inflammation rapidly provokes a proliferation of lymphatic endothelial cells.  [37] 
In literature there are few studies about lymphatic vessels in atherosclerotic carotid plaques. 
Nakano et al. researched coronary atherosclerotic arteries, and they observed that lymphatic vessels 
predominantly locate in the intima layer. [38] 
According to Kholova, in atherosclerotic coronary lesions, full of calcium crystals and cholesterol, a 
relevant lymphogenesis is the intima and media level; instead on an adventitia level, there isn’t a 
proliferation of lymphatic vessels.  [39] 
Meanwhile, in another investigation lead by Xu and his collaborators, they found that lymphatic 
vessels are primarily localized at the level of the adventitia. A second study, carried out by Drodtz, 
progressively confirmed such fact concerning 20 atherosclerotic carotid plaques, where lymphatic 
vessels, identified at adventitial and pre-adventitial level, were marked with Lyme-1 and with an anti-
podoplanin antibody. [40]  
Eliska et al., in their analysis regarding healthy coronary and atherosclerotic arteries, concluded that 
lymphatic vessels were only present in specific fit arteries in the periadventitial region. They also 
discovered that such vessels, both in healthy coronary and in atherosclerotic ones, did not overstep 
the adventitial layer, not going through the medium and the intima of the vessel. [41] 
Based on the complexity of the atherosclerotic lesion, the number of adventitial lymphatic vessels 
could seem to expand. Drodtz, in an analysis directed on atherosclerotic plaques of big abdominal 
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human vessels (aorta and iliac arteries), took in that the total of lymphatic vessels augments with the 
progression of atherosclerosis as assessed by the intima layer. According to the author, there is a 
statistically significant (p<0.05) correlation between adventitial lymphatics (marked by Lyme-1) and 
the intima thickness and the patients’age. [42] 
The role of lymphatic vessels in atherosclerotic plaques is not yet known. It is thought that the 
lymphatic system, like in normal conditions, has three functions: the maintenance of the balance of 
interstitial fluids, transport and cholesterol’s and lipid metabolism, and they take part in the immune 
response.  
 
Figure 6 Role of lymphatic vessels 
 
Nakano and his colleagues found that lymphatic vessels played a vital role in the interstitial fluid’s 
outflow from the atherosclerotic carotid plaque. They noticed that the number of lymphatic vessels 
in atherosclerotic coronary arteries was inferior to the number of adventitial lymphatic vessels 
within healthy coronary arteries. This fact would determine the growth of interstitial fluid in 
atherosclerotic plaques, an increase of pressure in the plaque and an alteration in the equilibrium of 
interstitial fluids. 
As a result, this causes an alteration of oxygenation, microcirculation of the plaque, and the following 
progress of the atherosclerotic lesion and the breakage’s risk of the same. [38] 
Lymphatic vessels, in particular adventitial ones, could be involved with the transportation of 
cholesterol in accumulated lipids from the artery wall to the blood. 
In a study conducted on hypercholesterolemic apoe-/- mice that cause structural and functional 
insufficiencies of the vessel’s wall, cholesterol is accumulated in the vessels’ walls. 
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Therefore, they reported that the reactivation of the normal vessel’s structure and of the liquid’s 
drainage on behalf of lymphatics would improve the clearance of cholesterol and of plaque’s lipids. 
[30]   
The clearance’s reduction of the cholesterol attributable to an alteration of lymphatic vessels 
determines the accumulation of cholesterol and lipids in the carotid atherosclerotic plaque.  
Lastly, lymphatic vessels actively partake in the transportation of immune cells. The stockpile of 
lipids and cholesterol can activate pro-inflammatory cytokines (i.e., TNF α) and reactive species of 
oxygen, which further accelerates the inflammation of the atherosclerotic plaque, recruiting other 
useful inflammatory cells essential for the progression and variability of the plaque. [43] 
 
 
Neangiogenesis in atherosclerotic plaque  
 
The presence of new blood vessels in the atherosclerotic plaque and their absence in the intima layer 
of the vessel in normal conditions, were firstly described by the anatomopathologist Paterson in 1936. 
[44] 
In 1980 researchers started to focus on intraplaque new vessels, and the percentage of angiogenesis's 
studies increased considerably from 0.2% in 1984 to 2.8% in 2007.  [45] [46] 
The leading cause which governs neoangiogenesis is hypoxia, as indicated in several of Sluimer’s 
investigations. The shortage of oxygen inside the atherosclerotic plaque determined by the activation 
of intraplaque inflammatory cells (i.e. monocytes and macrophages). 
Hypoxia determines the release, on behalf of inflammatory cells, of hypoxia-inducible factors (HIF) 
and of metalloproteinases (MMP-2, MMP-9), which participate in the instability of the plaque. 
The new blood vessels originate from the migration and proliferation in the vascular areas of 
endothelial cells coming from adventitial vasa vasorum [47], mainly stimulated by the VEGF-A. 
VEGF and its principal receptors (VEGFR-1 e VEGFR-2), which nurture the proliferation and 
formation of tubules throughout the neoangiogenesis. 
Angiopoietin 1 and 2 are ligands of the Tie-2 receptor of endothelial cells, and they cover a 
fundamental role during the final phase of the maturation of the new vessel. HIF and VEGF-A, 
therefore, induce Ang-2 to destabilize the interaction between pericytes and endothelial cells, 
allowing the vessel to develop. Ang-1, together with the growth factor deriving from platelets, on the 
contrary, it covers the role of stabilizing junctures between endothelial cells, encouraging the vessel’s 
stability. [48]   
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New vessels are fragile, immature, and irregular as compared to vasa vasorum [49], they are 
characterized by a disjointed basement membrane and by a low number of junctures narrow between 
endotheliocytes. [50] 
Their brittleness causes accretion of the breakage’s risk, thus a threat of intraplaque’s hemorrhage 
making the plaque vulnerable and increasing the hazard of the appearance of cardio-cerebrovascular 
events. As is generally known in the literature, the close relation between new intraplaque vessels and 
the danger of a plaque’s fracture does exist. [51]. 
Moreno et al. observed that the density of newly formed microvessels was higher than that of complex 
lipid plaques as compared to calcific plaques. Furthermore, they noticed that new vessels’ thickness 
was superior to that of plaques, where there was an important inflammatory infiltrate. Thus, new 
vessels facilitate the entry of inflammatory cells in the plaque.  
Jeziorska et al. highlighted that within 92% of analyzed plaques, neovascularized areas are located in 
the vicinity of areas that contain a crucial inflammatory infiltrate, primarily represented by 
macrophages, T lymphocytes, and mast cells. [52] 
New vessels show a rising expression of adhesion molecules, such as E-selectin, CD-40, ICAM-1, 
VCAM-1. In a study that was conducted by O’Brian, he noted that the manifestation of V-CAM-1 in 
the coronary artery plaque is rarely represented by endotheliocytes of the lumen (20%). Although, it 
is mostly displayed in areas intraplaque neovascularisation, rich in the inflammatory infiltrate, 
proving the pivotal role hematic new vessels in enrolment of inflammatory cells. [53] 
Moreover, the transfer of red blood cells through new intraplaque vessels depicts another necessary 
passage within the creation of the ‘vulnerable’ plaque. Hemoglobin, thus, provokes oxidative tissue 
damage, with the formation of oxidizing agents (i.e., cox, INOS).  
The removal of hemoglobin, in the form of heme-haptoglobin, takes place through macrophages 
with a link employing CD163. The production of oxidizing agents negotiated by haemoglobin 
activates the factor of pro-inflammatory transcription NF-KB that promotes the fabrication of pro-
inflammatory cytokines and the cellular recruitment of monocytes/macrophages and T 









AIM OF THE RESEARCH 
 
The primary prevention was implemented through the correction of risk factors, that include: the 
reduction of arterial pressure values below 140/90 mmHG, LDL cholesterol values under 100 mg/dl 
and triglycerides beneath 150 mg/dl and an increase of the ‘high-density lipoprotein’ HDL to superior 
values of 40 mg/dl.  The secondary preclusion was characterized by pharmaceutical therapy 
(antiplatelets/anticoagulant and statins) and by surgical therapy (carotid thromboendarterectomy and 
carotid stenting), which are both fundamental in order to forestall the progression of ischemic 
cerebrovascular events. These prove to be grade A recommendations according to the surgical 
vascular society [56].  
 
The analysis of macroscopic characteristics concerning the atherosclerotic carotid plaque, the degree 
of stenosis and the plaque’s morphology, carried out via diagnostic radiology investigations (carotid 
ECD, CT scan and/or MRI) currently represent the factors based on the indication of 
surgical/pharmaceutical treatment for patients affected by carotid stenosis. Although, the 
macroscopic study of the carotid plaque doesn’t allow us to identify the likelihood of cerebrovascular 
events and the timeframe of such events from the diagnostic radiology.  
 
With regards to immunohistochemical features of the plaque, with cytokines produced by the 
inflammatory infiltrate and on the neoangiogenesis, many scientific literature studies do exist, but the 
real mechanisms at the heart of the growth of the atherosclerotic carotid plaque and its instability are 
not known yet. We are aware that the evolution and the stability of the atherosclerotic carotid plaque 
rely on the inflammatory properties of this last one.  
The gradual progression of the atherosclerotic carotid plaque is especially caused by the creation of 
new vessels, that are responsible for the migration of inflammatory cells and the intraplaque 
hemorrhage. In parallel with the generation of new blood vessels, we witness the advancement of 
new lymphatic vessels, which role appears to be still unknown.  
During our previous studies of the plaques, the lymphatic vessels in the plaque had been identified 
involuntarily and surprisingly. 
The curiosity about lymphatic vessels in the carotid atherosclerotic plaques led to the birth of this 
study.  
In particular, the aim of this research is the identification and localization of lymphatic vessels in the 
atherosclerotic carotid plaques and the evaluation of the relationship between neo-lymphatic vessels 
with new blood ones and inflammatory cells. 
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In the future the comprehension of the existing connection between neoangiogenesis and 
neolymphogenesis and inflammatory infiltrate could be the foundation on which to build predictive 
models of vulnerability identifying premature patients with carotid stenosis at risk of evolving into a 
TIA or an ischemic stroke.  
In this regard, it is essential to deepen the microscopic study of the atherosclerotic carotid plaque in 
order to pinpoint possible pharmacological treatments to antagonize the atherosclerosis’ process or 




MATERIALS AND METHODS 
 
Patient’s recruitment and clinical characteristics 
 
31 patients with carotid stenosis have been recruited for this study; they have undergone Carotid 
Throm-boendarterectomy (TEA) surgery. 10 morphologically hard plaques have been used to 
develop procedures.   
Thus, 21 plaques were analyzed in this study. Out of the 21 patients involved in the research, 
anamnestic-clinical information of interest has been collected. The gathered information includes sex, 
age, symptomatology, comorbidity, anti-hypertensive, hypoglycaemic, and lipid-lowering.   




Patients affected by autoimmune diseases, neoplasia, or recent infections, have been excluded. 
The 21 enrolled patients presented an average age of 73; 14 patients were male (67%), and 7 were 
female (33%). 9 patients were symptomatic (43%), and 12 were asymptomatic (57%) due to cerebral 
ischemic events (TIA and or a stroke). 
Patients have been considered symptomatic if they could have presented an ischemic transient attack 
or a stroke in the carotid distribution territory in the previous six months [54].  
They were not considered symptomatic, based on OMS’s definition, patients with a positive medical 
history including loss of consciousness, vertigo, global transient amnesia, drop attack, generalized 
asthenia, and state of confusion.   
Of the 9 symptomatic patients (2 females and 7 males), TIA has been diagnosed in 6 cases, and a 
minor strike established in 3 cases. 
90% of patients were affected by arterial hypertension, 71% by dyslipidemia, 29% by mild renal 
impairment, 19% by diabetes mellitus, 20% by cardiac diseases, 14% by obstructive pulmonary 
illnesses, and 62% were smokers. Three patients (14%) suffer from glucose intolerance, and they 
show glycemic values on an empty stomach above 125 mg/dl.   
Amongst the primary clinical evaluated outcomes, in addition to TIA/stroke and perioperative death, 
the atherosclerotic cardiovascular disease risk (ASCVD risk) was also assessed, which is defined as 
the risk of myocardial infarction and of a stroke in 10 years. These results are based on an equation, 
which takes into consideration a patient’s race and age, the total cholesterol (with levels between 130 
mg/dl and 320 mg/dl), HDL cholesterol (20-100 mg/dl), average systolic pressure, presence of 
pharmacological treatment for arterial hypertension, diabetes mellitus, and smoking.  
The ASCVD’s average risk in 21 patients is 33,88%; in patients who are carriers of morphologically 
soft plaques, the percentage is 30,06%, and in mixed plaque-carriers are 41,54%.  
Eighteen patients swallowed at least one anti-aggregating/anti-coagulant medicine. (The three 
patients who did not take such prescriptions manifested a cerebral-vascular ischemic event, and they 
revealed morphologically soft plaques). 17 of the patients (81%) followed a pharmacological therapy 
with statin; 12 patients proceeded with atorvastatin with a comprehensive dosage between 20 and 80 
mg/daily; 3 patients took simvastatin of  20 mg/daily; 1 patient’s therapy requested a dosage of 10 
mg/daily and another who had to take 10 mg of ezetimibe jointly with simvastatin 20 mg/daily.  
Furthermore, 7 patients (33%) who were treated with β-blockers medications and 15 patients (71%) 
were cured with ace inhibitors, and 6 patients (29%) took calcium channel blockers. The four patients 
affected by diabetes mellitus were on a pharmaceutical therapy with oral hypoglycaemic agents, and 
no one assumed insulin.  
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All patients underwent a complete clinical and neurological pre-operative evaluation. Thus, during 
the pre-op phase, the patient was exposed to an instrumental investigation on supra-aortic vessels 
employing EcoColorDoppler. This medical test ran in order to analyze the morphology and 
composition of the atherosclerotic plaque (lipidic (soft), mixed or calcified (hard), to consider the 
plaque’s surface (regular, irregular, ulcerated) and its stenosis level. Before proceeding with 
surgery, every patient was subjected to carotid computed-tomography angiography and intra-cranial 
circulation to deliver accurate measurements on the stenosis level and to precisely give an estimate 
of the plaque’s composition through the “Hounsfield value”. (tab. 2) [55] 
Hounsfield Units (HU) Composition of the plaque 
20 - 60 Lipid (soft) 
60 - 130 Mixed 
≥ 130 Calcific (hard) 
Table 2 Hounsfield Units range 
 
All symptomatic patients went through a CT brain and a magnetic resonance imaging (MRI) of 
brain diffusion-perfusion for the analysis of ischemic wound’s outcome. Moreover, all patients had 
to go through medical investigations before the operation in order to obtain a pre-operation analysis: 
ECG, complete hematic routine, and a thorax’s X-ray.  
The enrolled patients experienced a carotid revascularisation’s surgery through carotid – 
thromboendarterectomy (TEA) by semi-eversion at the Unit of Vascular Surgery of University 
Hospital Macchi, ASST Sette Laghi, in Varese, Italy.  
Carotid TEA was implemented according to the European Society for Vascular Surgery’s (ESVS) 
guidelines under which symptomatic patients must be treated if they show carotid plaques super by 
50% (NASCET) with a risk of a stroke or of a perioperative mortality 6%.  
With regards to asymptomatic patients, they are treated when they present carotid stenosis included 
between 70 and 90% with a post-surgery risk of stroke and minor death of 3%. 
Twenty-one patients presented medium stenosis of 78,33%, measured according to Nascet’s criteria: 
13 (62%) carotid plaques were morphologically soft, and 8 (38%) were morphologically mixed. In 
patients with soft-plaque the medium stenosis is 79,61%, and in the mixed ones, it is of 77,85%. 
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The operations executed on 21 patients were carried out via under-local regional anaesthesia and they 
ran clinical monitoring. Afterward they performed Transcranial Doppler (TCD) for the analysis of 
possible embolic manifestations during the cross-clamping and declamping maneuvers and for the 
evaluation of compensatory effect determined by Willis polygon. It was not necessary to position a 
shunt. The medium clamping time was 22 minutes. There was no sign of TIA, stroke or perioperative 
mortality  
The atherosclerotic carotid plaque resulted from the carotid TEA was initially placed in 
physiological solution at 37° to remove blood residues from the surface, and it was successively 
positioned in paraformaldehyde at 4% and sent for microscopic immunohistochemical analysis. 
 
Immunohistochemical analysis: preparation and sample’s processing 
 
The atherosclerotic plaques collected after the TEA carotid surgery, have been put in 
paraformaldehyde at 4% phosphate swab for at least 48 hours and sent to MIA’s Consortium 
laboratory of Milano-Bicocca for immunohistochemical analysis. At the laboratory, as fixation 
occurred, the plaque was included in paraffin using automatic processors based on a standard 





 Ethanol 70% 60 22° 
Ethanol 95% 90 22° 
Ethanol 95% 120 22° 
Ethanol 100% 60 22° 
Ethanol 100% 90 22° 
Ethanol 100% 120 22° 
Xylol 120 22° 
Xylol 120 22° 
Paraffin 90 60° 
Paraffin 90 60° 
Paraffin 120 60° 
Table 3 Reagenta, timing and temperature of samples 
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Once paraffin is soaked in, the pieces are included in biology pathology boxes, and from the 
embedded tissues, slices of 3-10 µm are obtained, and they are assembled on the slide compartment, 
using a steel blade microtome.  
For an initial histochemical analysis, the obtained samples are dyed in hematoxylin-eosin. 
Hematoxylin-eosin is a two-toned coloring based on the different pH measure of the various tissues 
and organelles components of the cell. The nucleus and the cytoplasm’s acidic elements (ribosomes, 
acid secretion) are colored in purple from hematoxylin, which is a basic colorant. Meanwhile, the 
cytoplasm and the different kinds of basic tissues (muscular, connective, and bone) are dyed in pink, 
more or less intense, from an eosin’s acid mixture. 
Other slide sections are used to identify immunohistochemical investigations through the use of 
specific antibodies that allow characterizing cellular and tissue components.  
Numerous passages executed in different reagents:  
• Himmuno-phosphatase on paraffin  
• Xylol: 2 passages, 30 minutes long 
• Alcohol 100°: 2 passages, 3 minutes long 
• Alcohol 96°: 1 passage, 3minutes long 
• Distilled water: 2 swift passages  
 
At this stage it is possible to carry out the antigen exposure (if required).  
For identification, slides are placed in EDTA 0,1mM or on a 5mM citrate swab in the designated 
containers. Such containers are placed inside a pressure cooker containing 700 ml of distilled water. 
The distilled water is brought to boil. After that, the lid is closed for about 5 minutes. After going 
through this phase, the pot is removed from the grill and brought back to ambient pressure by 
opening the valve. 
This operation is repeated for a total of three passages. Subsequently, repositories are removed out of 
the pressure cooker, and after 5 minutes, lids are opened. 
Slides are washed 3 times, for 5 minutes, with TBS (tris swab 0,5M in buffered saline solution and 
Triton)  
It is necessary to proceed by drying the slides and processing them as it follows:  
• PBS+BSA (phosphate buffer solution 0,05M in bovine albumin in saline solution at 1%).  
• Primary antibody 1h RT (alternatively ON at 4°) 1 passage, 10 minutes long  
• Rinse slide with TBS+T one by one 
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• TBS+T 3 washes, 5 minutes long 
• Biotinylated secondary antibodies (AB2 Dako REAL K5005): 1 passage, 15 minutes long 
• TBS+T: 3 washes, 5 minutes long  
• Streptavidin conjugated with alkaline phosphatase (AP Dako REAL K5005): 1 passage, 15 
minutes long 
• TBS+T: 3 washes, 5 minutes long 
 
Progression in chromogen prepared according to the advisable procedure in the kit (RED Dako 
REAL K 5005): after 20-30 minutes check on the microscope:  
• Counterstain with Carazzi’s hematoxylin 
• Rinse with springwater 
• Dry the slides 
Soft and mixed plaques have been examined, and for each plaque, each marker has been taken into 
account:  
• CD3 antibody used for T lymphocyte identification  
• CD 4 antibody used for T lymphocyte (helper) identification  
• CD8 antibody used to identify cytotoxic T lymphocytes  
• CD11b antibody used to recognize cells of the monocyte-macrophage line, especially taking 
action on the admission and phagocytosis performed by macrophages.  
• CD14 antibody used for the recognition of monocytes during their distinction 
• CD34 antibody used to determine progenitor cells of the hemopoietic line and endothelial 
cells.  
• CD66b antibody used to label triggered neutrophils 
• CD68 used to identify macrophages (lysosomes, phagocytosis capability) 
• CD163 antibody used for the identification of monocytes/macrophages 
• CD208 antibody used to put a name on dendritic cells  
• CD 209 antibody used to identify dendritic cells  
• IL-8 chemokine is pro-inflammatory and pro-angiogenic. Produced by endothelial cells, 
macrophages, and muscular cells.  
• TGF-β growth-factor beta that monitors the cellular proliferation 
• TRYPTASE antibody used to identify mast cells  
• INOS (inducible nitric oxide synthase) enzyme that produces nitric oxide 
• ULEX marker used to determine endothelial cells of blood vessels of different sizes 
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• HLA-DR transmembrane molecule expressed by T lymphocytes, activated lymphocytes, 
macrophages, and monocytes.  
• MMP-2, MMP-9 metalloproteinases able to downgrade various proteins of the extracellular 
matrix 
• Neutrophil elastase: protease produced during inflammatory processes able to degrade the 
extracellular matrix  
• Arginase 1 enzyme, which hydrolyzes with an inflammatory effect  
• D2-40 (podoplanin) marker used to identify lymphatic endothelial cells 
• Ki67 useful for the assessment of the cellular proliferation from G1phase  
 
Immunohistochemical coloring has been scanned using Aperio Technologies®, Vista, California, 
U.S., and quantified using the MATLAB®portal.  
Certain carotid atherosclerotic plaque sections have been analyzed via confocal microscope.  
 
 
Automatic analysis’ software 
 
A designated software has been invented in collaboration with department of the University of Studies 
of Milan, in order to carry out a quantitative and reproducible assessment of the images obtained from 
immunohistochemical analysis, that will allow not to lose sight of the entirety of the plaque, where 
markers do not appear evenly spread throughout.  
This software authorizes automatic analysis, which is repeatable and quantitative of the images that 
came out of the immunohistochemical examination of the carotid atherosclerotic plaques.  
In order to re-elaborate them, immunolabelled sections have been scanned, producing hundreds of 
digital colour images (RGB) of large size/resolution (often >4Gb). This software uses Matlab’s 
language for automatic tracking (segmentation) of markers, from digital colour images of sections of 
the immunolabelled plaque with alkaline phosphatize.  
After segmenting markers, the software must quantify:  
• The consistency of distribution of markers in every section (section’s density) and in all 
divisions of one same patient (a parient’s solidity);  




• An image (map) of localization for each segmented marker and an image (map) which shows 
tracking of all different markers segmented by standard sections, which show the same 
plaque’s area;  
• Measurements which enable the comparison between two maps, or among one map and 
morphological structures, identified by expert users, who describe the macroscopic shape of 
the section.  
In this regard, algorithms have been realized to segment the section’s interest area (ROI), excluding 
it from the “background” of bright colour. Therefore, in the ROI algorithms of segmentation of 
markers have been applied, namely, the algorithms that look for pixel’s areas of various shapes, 
characterized by an ‘averagely’ red colour.  
Segmented areas have been quantified by measuring density per section and patient, and they have 
been visually located through the creation of maps to whom should be applied suitable 
transformations of distance for the mutual comparison. These transformed must resume both 
comparative relations among maps and the contrast between a map and the morphological structures 
of a plaque.  
There are some problems linked with the software, and they are characterized primarily by substantial 
sizes and resolutions of each image, as high computational costs occur in terms of space and time. To 
resolve this set of problems, experts have developed fast and straightforward computational 
algorithms, which are independent of global image features (i.e., medium luminance, medium 
contrast) to apply to image’s subregions and to progressively put together the achieved results. 
Another set of problems is represented by the presence of pigments with a structure and colouring 
similar to that of markers, to segment with the possibility of achieving an inaccurate segmentation of 
unspecified structures with similar colour shades (false positives). For this reason, in order to obtain 
sensible segmentation results (low or invalid marker loss, or somewhat elevated percentages of true 
positives) and specific results ( low or invalid percentage of false positives), they have designed 
software capable of learning examples semi-automatically given by expert users. Values of pixels 
establish the examples in the images of sections and of their label (ground truth) of marker pixels 
(pixels that belong to markers) and no-marker pixels.    








Immunohistochemical analysis was executed on 10 atherosclerotic carotid plaques hard in the first 
part of the investigation.  
In spite of the trouble had with the preparation of slides, in relation to the difficulties of cutting the 
same ones for the presence of intraplaque calcium, from the analysed data it has been observed that 
there is an absence of inflammatory cell population, a lack of inflammatory cytokines and molecules 
and lymphatic and arterial vessels in hard atherosclerotic plaques.   
Therefore, our study went on by enlisting patients who were bearers of, morphologically defined, soft 




Figure 7 Immunohistochemical analysis of soft atherosclerotic carotid plaque 
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Immunohistochemical analysis of atherosclerotic carotid plaques, using different markers, which 
identified cells and molecules that were involved with inflammatory and neovascularisation, has 
shown an extreme variability of expression amongst the several inspected plaques, notwithstanding 
that areas neighboring the lipidic and the fibrous cap have been evaluated.  
Making a comparison with immunohistochemical images obtained after the analysis of two plaques, 
one lipidic and one mixed, it is observed that the markers’ display is very variable (fig 7-8).  





Figure 8 Immunohistochemical analysis of mixed atherosclerotic carotid plaque 
In the soft inspected atherosclerotic carotid plaque’s portion (fig. 7), especially in the first section 
coloured with hematoxylin-eosin, it is possible to observe the presence of an important inflammatory 
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infiltrated. It is mainly represented by cells of the monocyte-macrophage line (CD-11b, CD-14, CD-
68, CD-163), by T lymphocytes (CD-3, CD-4, CD-8), by dendritic cells (CD-208, CD-209), by 
(Tryptase) mast cells and also by the existence of molecules implied with cellular proliferation (Ki67) 
and with inflammatory-atherosclerotic process: metalloproteases, Elastase, arginase 1, TGF-β, Cox-
2, IL-8 ed Inos.   
Such markers result to be less expressed in the mixed atherosclerotic carotid plaque examined in 
picture 8. In such plaque, we can observe the presence of an inflammatory lymphocyte T infiltrate 
weakly expressed in CD4 and the presence of a few cells of the monocyte-macrophage line, 
predominantly CD-163. Even the molecules’ expression implied in the inflammatory-atherosclerotic 
is weak. 
Taking into consideration the extreme display variability of the markers inside the atherosclerotic 
carotid plaques and the extremely changeable nature of plaques amongst different patients, the focus 
was on new hematic and lymphatic vessels, and macrophage and lymphocytic. 
 
 




Regarding new hematic vessels, inside the atherosclerotic carotid plaque numerous studies in 
literature exist and their immunohistochemistry identification results simple, appearing as they 
composed by a single layer of mature endothelial cells. Furthermore, they do not result flatted and 
they present tubular structures. To recognise blood endothelial vessels markers are multiple, and we 
have made the decision to use ULEX e CD-34 (Fig. 9). 
On the other hand, to date, investigations on lymphatic vessels are less copious and at times their 
identification appears demanding because they look like flatted structures constituted by a single-
layer of lymphatic endothelial cells (Fig. 10). The most utilized markers to classify the lymphatic 









Considering the radical heterogeneity of the sample and the difficulty to recognise lymphatic 
endothelial cells, with a view to have confirmation that the pinpointed vessel were actually new 
lymphatic vessels, a double marking was done with D2-40 3 VEGFR3 on atherosclerotic carotid 
plaques using a confocal microscope. Thus, going through an analysis on the confocal microscope, 
in picture 11a two vessels made of lymphatic endothelial cells in red are observed.  
Thereupon, a confocal estimate was carried out on a section adjacent to the first, of labeling with 
VEGFR3 (VEGF’s receptor typical of lymphatic endothelial cells), identified in the colour blue (fig. 
11b). Lastly, another section adjacent to the first ones, with double marking, was studied closely on 
the confocal microscope (D2-40 e VEGFR3). This confirms that immunolabelling structures show 




Figure 11 Lymphatic vessels marked with D2-40 (red, a) and VEGFR-3 (blue, b) by confocal microscope, double marking (c). 
 
 
Thence, new hematic and lymphatic cells, present in morphologically soft atherosclerotic plaques and 
in mixed ones, were evaluated.  
The first section of a soft plaque (Fig. 12a) has been marked by hematoxolyn-eosin and shows the 
presence of an important inflammatory infiltrate scattered in the whole section. 
In picture 12b-c the new hematic vessels have been marked with CD-34 and Ulex, they characterized 
by a single-layer of endothelial cells. On the contrary, in picture 12d the plaque’s section has been 
marked with D2-40 locating in a different place compared to that of hematic vessels, away from the 
stringy cap, the new lymphatic flatted vessels. 
 
 





Figure 12 Immunohistochemestry analysis of soft carotid plaque: a-hematoxolyn-eosin, b-c-blood vessels (Ulex, CD34); d- lymphatic vessels (D2-40) 
 
In the atherosclerotic carotid mixed plaque analyzed using hematoxylin-eosin (fig. 13a), it is observed 




Figure 13 Immunohistochemestry analysis of mixed carotid plaque: a-hematoxolyn-eosin, b-c-blood vessels (Ulex, CD34); 
 d- lymphatic vessels (D2-40) 
 
Furthermore, after the section’s colouring with Ulex and CD34 (fig.13 b-c) new vessels aren’t 
identified. It is observed that there’s a colouring on the stringy cap’s surface symbolised by intimal 
endothelial cells. In figure 13d the presence of endothelial lymphatic cells is not seen.  
The immunohistochemical assessment allows us to evaluate only small plaque areas. This can lead to 
a loss of an overview of the atherosclerotic carotid plaque, as inside the plaque markers have an 
extreme variability of display and they don’t result as evenly distributed. 
a b c d 
a b c d 
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For this reason, immunohistochemical images of the atherosclerotic carotid plaque have been judged 
using a specifically developed software, it allows to examine the entire plaque, speeding analysis’ 
duration of all plaques and granting a comparison amongst them. The given results, (concerning 
predominantly consistency and distance between lipidic/necrosis core and dissection plan), are 
comparable amongst them, reproducible as it regards an automatic analysis of all immunolabeled 
sections of every single plaque.   
As previously seen in figure 13, D2-40’s display, lymphatic vessels’ marker, in a morphologically 









































D2-40 Lymphatic vessels (b) 




In the soft plaque, the greatest of D2-40 is visible near to the lipidic core. With regards to blood 
vessels (fig.14c), they are present in both analysed plaques, mostly in the vicinity of the surgical 
margin and showing no relation with the lipidic core.  
The last two sections (fig. 14d) depict a segmentation example (a process of automatic analysis from 
the software) of the plaque. The lymphatic vessels are represented with a red colour, whereas hematic 
vessels are depicted with a green colour. 
The automatic software analysis obtained a localization map of two types of new vessels and it is 
observed that the red colouring is missing in the mixed plaque, whereas it is well depicted in the 
lipidic plaque near to the lipidic core. In both plaques, the hematic vessels, in green, have a casual 
arrangement, primarily close to the stringy cap and the surgical margin. 
 
 
Figure 15 Soft plaque: colouring with D2-40 (a), Ulex (b), Automatic segmentation by software (c) 
 
In picture 15 it is noted that there’s an expansion of one section of the atherosclerotic carotid lipidic 
plaque. The lipidic core and the position of the lymphatic vessels around it are well noticeable 
(fig.15a), whereas blood vessels are located far away from the lipidic core near the cap (fig.15b). 
Conclusively, an automatic segmentation was also performed on this section using the software of 
the analysed plaque, which has allowed us to deeply monitor the position of the lipidic vessels around 
the lipidic core. 
By using the software all structures of mixed and lipidic plaques have been examined, and D2-40’s 
density has been evaluated through the software, in each section and all sections of one same patient, 
b a c 
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gaining a numerical value that is repeatable and comparable. Different sections were standardized 
automatically by the software for a correct comparison between different plaques.  
 
      
Table 4 D2-40 density in soft and mixed carotid plaques and in the graph: distribution of lymphatic vessels density in the mixed plaques (blue) and 
soft ones (orange). 
 
From the automatic analysis using the software, density values of mixed and soft lymphatic vessels 
were extracted (table.4). As also noted on the histogram, the density of lymphatic vessels in the 
atherosclerotic lipidic plaque (medium value 0,0128) is greater than mixed plaque (medium value 
0,000295), and such dissimilarity is statistically significant with p<0,05. 
For a better understanding of the origin and function of lymphatic and hematic vessels inside 
atherosclerotic carotid plaques, some components of the inflammatory infiltrate were examined, 
particularly, T lymphocytes (CD-3) and two different macrophage populations (CD-68, CD-163) 
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Figure 16 Immunohistochemistry analysis of carotid plaque marked with Ulex (a), CD-3 (b), double marking on the confocal microscope (ulex red, 
CD-3 yellow) and D2-40 marked (d). 
 
Figure 16a represents an atherosclerotic carotid plaque’s section marked with Ulex to identify 
endothelial hematic cells. Picture 16b shows a colouring with CD-3 and it enables the identification 
of T lymphocytes. As observed in these pictures, hematic vessels tend to co-locate with T 
lymphocytes. Such information is confirmed by the double-marking on the confocal microscope 
(fig.16c), where the lymphocytes CD-3 coloured in yellow are near endothelial hematic cells marked 
with Ulex in red colour. 
T lymphocytes and hematic vessels are not localized in the same territory that is occupied by 
lymphatic vessels marked with D2-40 (fig.16d).  
With regards to the inflammatory infiltrate of macrographic origin (CD-68, CD-163) it is mainly 






Two sections of atherosclerotic carotid marked plaques with D2-40 have been shown in figure 17a, 
to identify lymphatic endothelial cells. They arrange themselves around the lipidic core, together with 
macrophage cells CD-68 (fig.17b). The co-location of lymphatic endothelial cells and macrophage 
cells was proved by a double-marking on the confocal microscope (fig.17c).  
In figure 17c lymphatic vessels are seen in red, macrophage cells are observed in green. The blue 
colouring is defined by nuclear staining, which is typical of the methodology. 
 
Figure 17 Immunohistochemistry analysis with D2-40 (a), CD-68 (b), and double marked by confocal microscope. 
 
The co-location analysis of lymphatic vessels’ and macrophage cells was further scrutinized by way 
of immunofluorescence in confocal microscopy. Taking advantage of the resolution power of 
confocal microscopy, it observed that only rarely we can find tubular open structures attributable to 
one or two collapsed lymphatic vessels (fig.18a, red). This is frequently seen in structures that could 
also be isolated cells (fig.18b, red) near macrophage cells CD68, coloured green. In some cases, cells 








Figure 18 confocal microscope: lymphatic vessels (red), macrophage cells CD68+ (green) 
 
To characterise macrophage cells and to better understand how they could influence new lymph 
genesis, an analysis of macrophage cells CD-68 was done on the confocal microscope with double-
markings.  
As seen in picture 19, the first section of the plaque was marked with CD-68 (fig.19a, green) and it 
shows the presence of a macrophage cell. The following section, forthwith adjacent to the first, was 
marked with HLA-DR (fig.19b, red), showing cells that present HLA-DR topside. Conclusively, 
double-marking was implemented with CD-68 and HLA-DR (fig.19c), which has highlighted that a 
few macrophages show positive labeling for CD-68, although they do not show topside HLA-DR. 
Such features are typical of myeloid-derived suppressor cells (MDSC) of the monocyte-macrophage 
line. 
 
Figure 19 Confocal microscope analysis: CD-68 marked (green) and HLA-DR (red) 
 
To achieve comparable and reproducible data, all soft plaque sections have been examined 
automatically, by the software, to obtain a localization image for each segmented marker (map), 
which shows the locations of all markers inside the atherosclerotic carotid plaque. Furthermore, the 
software has created maps, which have been compared by the software itself, attaining with precision 
a b c 
a b c 
36 
 
the distance of different markers from the lipidic/necrotic core and the surgical dissection plan (in 
pixels). 
 
Figure 20 map of localization of lymphatic vessels (D2-40, red), ematic ones (Ulex, blue), macrophages cells (CD-68, green) 
 
Figure 20 represents an example obtained from an automatic analysis of all sections of all 
atherosclerotic carotid soft plaques. The software has segmented markers D2-40, Ulex, CD-68 of all 
plaques and putting all the data together, it has given information regarding the distance between such 
markers from the lipidic core and the dissection surgical plan.  
This analysis, defined automatically by the software, has confirmed that inside lipidic plaques 
lymphatic vessels are located near the lipidic core, which co-locates with macrophage cells CD-68. 
Futhermore the software has confirmed that blood vessels are located far off lipid core/necrosis but 
near the surgical dissection surface. 
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Connecting the data obtained from automatic analysis of all immunoistochemical sections of all 
lipidic plaques, it is created an histogram. This one creates the connection between lymphatic vessels, 
blood vessels and inflammatory macrophage cells (CD-68 and CD-163) and lymphocytes T (CD-3) 
 
 
Graph 1 Histogram of lymphatic and blood vessels distribution with macrophage cells (CD-68, CD-163) and lymphocytes (CD-3) 
 
From Graph 4 it is plained that the expression of D2-40 (red line) is near the lipid core with its 
maximum peak between 0 to 400 pixels from lipid core. Macrophage cells CD-163 have a peak 
between 0 to 400 pixels (pink line) from lipid core and therefore macrophages are located near the 
lymphatic vessels and lipid core. 
Near lipid core and near macrophage cells CD-163 there is a peak of CD-68 cells, this peak is between 
0-200 pixels (black line). 
Blood vessels, in all lipid plaques, are homogeneously distributed between lipid core and surgical 
plan (green), they haven’t peak. Moreover lymphocites T CD-3 (blue line) follow the distribution of 










The atherosclerotic carotid plaque’s inflammatory process plays a main role in the instability of the 
plaque and its fracture.  
The extreme variability of the inflammatory cells of cytokines produced by the cells and new vessels 
present in atherosclerotic carotid plaques have made the investigation very complicated, with 
considerable evaluation difficulties amongst the analyzed plaques, particularly for the extreme 
irregularity of distribution of the different considered markers.  
The analysis appears to show a higher number of inflammatory cells, cytokines, pro-inflammatory, 
and new vessels inside soft plaques compared to mixed and hard plaques. Such information can be 
explained by the fact that soft plaques show a vast lipidic core, and they do not contain calcification 
areas occupying space. It is then clear that the atherosclerotic carotid plaque is not a static structure. 
However, it is a dynamic structure inside of which inflammatory cells play a fundamental role in the 
stability-instability process of the plaque itself. 
Numerous and still unknown are the signs and the balance between pro-inflammatory and anti-
inflammatory stimuli useful for the development of a neovascularization and plaque instability. 
Several pieces of research, with the example of Van der Wal et al. [59] and L. H. Arroyo et al. [60], 
have concluded that the presence of leucocytes and especially T lymphocytes, neutrophils, 
macrophages and inflammatory cytokines produced by them, may reduce plaque’s stability. 
These cells can generate cytokines and proteolytic enzymes (i.e., urokinase, plasmin, 
metalloproteinases MMPs) in the extracellular matrix. For example, the production of IFNγ on behalf 
of T lymphocytes reduces the proliferation of smooth muscle cells and the creation of collagen, 
making the plaque more vulnerable to breakage. At the same time, MMPs possess the capacity to 
decompose the extracellular matrix, making the plaque unstable. 
In this study we observed that is very important to evaluate lymphatic vessels and their correlation 
with blood ones because they have different position in the plaques and different relationship with 
inflammatory cells. 
In this study, we have observed the presence of lymphatic and hematic new vessels inside 
atherosclerotic carotid plaques. These new vessels tend to not position amongst each other. Blood 
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vessels expand themselves primarily away from the lipidic core, in the proximity of the fibrous cap, 
while lymphatic vessels situate near the lipidic core.  
There are several studies in which they mention that the stability of the atherosclerotic carotid plaque 
might depend on, as well as for the presence of a significant inflammatory infiltrate, it might also be 
determined by the presence of new blood vessels.  
According to Sluimer, there is a close relationship between the density of intraplaque new vessels, 
the growth and risk of fracture of the plaque.   [36] 
In our project, there is not a significant difference between the density of new lymphatic and blood 
vessels and the development of cerebrovascular symptoms. As commented in Moreno’s investigation, 
neoangiogenesis demonstrates a higher expression in lipidic plaques than in mixed and calcified 
plaques; it is also superior in plaques where there is a significant inflammatory infiltrate.  
It is believed that blood vessels play a crucial role in the entrance and exiting of inflammatory cells. 
More importantly, we have noticed that newly formed blood vessels co-localize with inflammatory 
cells, especially with lymphocytes CD-3. T lymphocytes determine the progression of a lesion and 
support apoptosis, producing cytokines that nurture the endothelial proliferation and advancement of 
new vessels. It would also seem that they would lower the proliferation of macrophages, causing a 
higher instability of the plaque. [61] 
Lymphatic vessels in all analyzed plaques have a superior density in lipidic plaques as compared to 
calcified or mixed plaques. 
For those investigations which are part of literature, the lymphatic vessels’ boundary inside 
atherosclerotic arteries is not univocal. According to Xu [62] and his associates, lymphatic vessels 
situate on the adventitia’s level, as in healthy vessels, which are positioned on the intima’s level, as 
stated by Nakano [50]  These tend to increase density with a growth of the intimal area, as declared 
by Kholova [51], ultimately at an intimal level and on media layer.   
Drozdz and his colleagues [54] [52] found a substantial correlation between lymphatic vessels 
pinpointed at an adventitial layer within atherosclerotic carotid arteries and the intimal area; therefore, 
the more significant that intimal area was, the more prominent was the LYME-1 ‘s (lymphatic 
vessels’ marker) expression at the level of the adventitia.  
In our study, we have observed that lymphatic vessels situate on media layer, and, in all plaques, they 
arrange themselves around the lipidic core, on the intimal area; we have not spotted any lymphatic 
vessels, but only blood vessels.  While, we have not considered the adventitial layer, as the cleavage 




Lymphatic vessels have three fundamental functions: maintain the balance between interstitial fluids, 
transporting inflammatory cells, and, finally, regulating the metabolism and the absorption of lipids. 
In normal conditions, they adjust the drainage and the stability of interstitial fluids in atherosclerotic 
plaques. As specified by Nakano, lymphatic vessels have little representation, mainly arranged at an 
intimal layer, thence they determine an increase of liquids and interstitial pressure, causing hypoxia, 
a progression of atherosclerotic lesions and breakage of the plaque. 
The arrangement of the lymphatic vessels around the lipidic core, inside the atherosclerotic carotid 
plaque, it allows us to hypothesize that the stimulus of the neo-lymphogenesis might be the attempt 
to absorb and metabolize lipids. Lymphatic vessels play a crucial role in the opposite transportation 
of cholesterol, mobilizing cholesterol’s macromolecules, and lipids from the peripheral site to blood.   
[63]  
According to Coso [64] in cardiovascular diseases and atherosclerosis, there is a dysfunction of 
lymphatic vessels and their functions. In a research study conducted on hypercholesterolaemic mice, 
the excessive accumulation of cholesterol and lipids in tissues determines structural and functional 
defects of lymphatic vessels.  [65] 
In fact, in the same model of hypercholesterolaemic mice, the reinstatement of the lymphatic drainage 
has established a better clearance of the cholesterol and lipids from the tissue [66] . This altered 
function of the lymphatic vessels sets a stockpile of lipids and cholesterol inside atherosclerotic 
plaques.  
It is, however, inexplicable how cholesterol HDL leaves the plaque. Martel and his collaborators have 
created a few models to explain such a mechanism. As specified by these authors, cholesterol pours 
out of the plaque following the interstitial fluid’s direction, and it merges inside the adventitial 
lymphatic vessels. They have increased the cholesterol in particular (using an isotope of the 
cholesterol) in atherosclerotic plaques of the murine aorta, and they have restricted the development 
of lymphatic vessels on the plaque’s level through the inhibition of VEGFR-3.  
As a result, they have monitored that cholesterol’s transportation blocked outside of the 
atherosclerotic plaque.  [67] 
Lymphatic vessels often located in the proximity of the lipidic core and in areas where the 
inflammatory infiltrate results very well represented. New lymphatic vessels seem to perform an 
activity of the transportation of inflammatory cells inside and outside of the atherosclerotic plaque.  
[68] 
The lipids’ stack can define the launch of inflammatory cells, which produce pro-inflammatory 
cytokines, such as tumor necrosis factor (TNF- α) and reactive oxygen molecules, that raise the local 
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inflammation. For this reason, anomalies at the expense of the lymphatic system set out the stash of 
inflammatory cells, toxic metabolite, and pro-inflammatory cytokines which facilitate atherosclerosis 
progression.  [69] 
Also, in our investigation, we have scrutinized a colocalization amongst lymphatic vessels and 
macrophage cells, CD-68 and CD-163 in particular.  
Macrophages in the atherosclerotic plaque play a crucial role in the phagocytosis’ process of lipids 
and cholesterol carrying the scavenger’s role out.  
From a phenotypic point of view, macrophages can divide into two groups: M1 macrophage, which 
is activated and stimulated by molecules, as, for example, IFN-γ, TNF-α. They secrete nitric oxide 
and pro-inflammatory cytokines (IL-1, IL-6, IL-12, IL-23) and TNF-α. Secondly, there are M2 
macrophages that have a potent anti-inflammatory activity (“Deactivated” macrophages) and incited 
by cytokines, such as IL-4, IL-10, and IL-12. Furthermore, M2 macrophages defined as regulators. 
Amongst the analyzed atherosclerotic plaques, we have identified macrophage cells CD-68 positive, 
which include all types of macrophages and macrophage cells CD-163 positive, that in most cases 
are M2 macrophages. 
Macrophages situate in proximity with the lipidic core s their fundamental role is to phagocytize lipids 
and cholesterol. Besides, they foster the removal of HDL cholesterol on behalf of lymphatic vessels 
even if only a few macrophages seem to come out of the atherosclerotic plaque through lymphatic 
vessels. [70] [71] 
Moreover, macrophages localize in the proximity of the lymphatic vessels and co-localize with 
themselves, probably because they represent inflammatory cells mainly involved in the 
lymphogenesis’ process. They nurture lymphogenesis via two methods: the production of paracrine 
signals represents the first one on behalf of macrophages; the second one is symbolized by the 
differentiation of macrophages in lymphatic endothelial cells.  
The first mechanism of macrophages that supports lymphogenesis, is determined by the up-regulation 
of VEGF-C during the inflammatory process inside the atherosclerotic plaque. In fact, macrophages 
produce TNF-α that activates the TNFR1 receptor facilitating the creating of the VEGF-C, which 
activates VEGFR-3 promoting the development and the activation of lymphatic endothelial cells. [72] 
In addition to the paracrine mechanism, macrophages contribute to lymphogenesis using 
transdifferentiation in lymphatic endothelial cells. In our study, we have monitored the confocal 
microscope, the presence of lymphatic endothelial cells (marked with D2-40), that expressed on their 
surface CD-68, macrophages’ marker. In literature, such data is confirmed thanks to investigations 
run on vitro and animals. For example, Hall, in vitro, has found on the level of the lymphatic 




The macrophagic cells’ in-depth research has allowed us to identify inside the atherosclerotic carotid 
plaque, the presence of CD-68 positive cells and HLA-DR negative cells. These are myeloid-derived 
suppressor cells (MDSC) of monocyte-macrophage origin.  
Myeloid-derived suppressor cells were described for the first time in tumors in 1970. [74] In spite of 
the numerous investigations carried out inside neoplasias, their phenotypical and functional 
characteristics are not entirely defined.  
These cells in neoplasias inhibit the immune response mediated by T lymphocytes, both in vitro and 
in vivo. [75] [76] The inhibition happens to regulate the immune response and to prevent excessive 
activation of T lymphocytes, which can develop an auto-reactivity, damaging healthy tissues. MDSCs 
facilitate tumor growth, releasing reactive species of oxygen, nitrogen, and nitric oxide and 
intensifying the inflammatory process.  [77] [78] [79]  
Moreover, myeloid-derived suppressor cells are involved in angiogenesis and lymphogenesis’ 
processes [80]. In literature, there are not projects in which myeloid-derived suppressor cells have 
been analyzed inside atherosclerotic carotid plaques. Wang and his colleagues have evaluated the 
presence of myeloid-derived suppressor cells in the blood of patients affected by acute coronary 
syndrome, stable angina, and healthy individuals. Wang et al. monitored a more significant 
suppression (higher MDSC expression, arg-1, IL-1β, IL-6, TNF-α) of T lymphocytes in patients 
affected by acute coronary syndrome as compared to patients with stable angina and healthy controls.  
[81] 
In our investigation, there are relatively small numbers of myeloid-derived suppressor cells and 
predominately arranged in the proximity of blood and lymphatic vessels; for this reason, it is thought 










The inflammatory process represents the cornerstone in the development of the atherosclerotic carotid 
plaque, but the literature’s facts are still lacking a definitive vision.  
The analyzed plaques in this study have allowed achieving preliminary and interesting results that 
show the presence of a new lymphatic and blood neovascularisation and to determine existing 
relations between such vessels and the inflammatory infiltrate, with a particular focus on 
macrophages and T lymphocytes.  
Through the use of the software, purposely created, it has been possible to examine plaques 
automatically and to obtain data that could be compared amongst each other, also amongst different  
patients, regardless of the variability of markers’ expression, between the analyzed areas of the same 
plaque and amongst different plaques.  
The distribution of blood vessels is variable, but they generally place in areas where the inflammatory 
infiltrate is abundant. Such information suggests that these vessels may regulate the entrance and exit 
of inflammatory cells inside the plaque.  
As illustrated by literature, blood vessels seem to make the plaque vulnerable and unstable in the first 
place because they appear composed of a single layer of endothelial cells; therefore, they are fragile, 
and can encounter a lesion; secondly, because they nurture the entrance of inflammatory cells inside 
the plaque.  
A new piece of information, not previously identified in the literature, is the localization of lymphatic 
vessels near the lipidic core. Undoubtedly lymphatic vessels inside atherosclerotic carotid plaques 
represent a new “actor” in the atherosclerotic process, although their role is still unknown. One of the 
keystone functions of lymphatic vessels is represented by lipids’ metabolism and cholesterol’s 
opposite transport, but it is not yet known if this function could make the atherosclerotic carotid 
plaque vulnerable, or if it could have a protective and stabilizing effect on the same.  
With such utter clarity, it is even more evident that in atherosclerotic plaques, there is a ‘reparative’ 
tendency of our organism, that starts in the ‘fatty streak’ deriving from the attempt made by 
macrophages to metabolize oxidized LDLs. It symbolizes the first evolution phase of the 
atherosclerotic plaque, which has a new phase made up of the creation of new lymphatic vessels.  
Lymphatic vessels could highlight the drainage attempt of the lipidic core. These phases depict 
different moments in the evolution of the atherosclerotic plaque, but they allow us to recognize how 
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the reparative tendency of the individual, mediated by immunity, may intervene in the 
physiopathology of the atherosclerotic lesion.  
For that reason, it will be necessary to increase the numerousness of the sample and considering new 
markers, which can allow us to define cholesterol metabolism, and lipids’ transport mechanisms with 
more precision, and so the function of lymphatic vessels and cytokines involved in such mechanisms.  
Another important, revealed by the study, is the co-localization of lymphatic vessels with macrophage 
cells. Macrophages are the principal cells involved in the lymphogenesis, via VEGF-C’s secretion. 
By increasing the study sample, we will be able to identify other cells implicated in such a mechanism, 
and some cytokines that might support the development of lymphatic vessels. Furthermore, it will be 
useful finding ways to pinpoint all macrophage subpopulations, both M1 and M2, with the intent of 
understanding how these populations may act on neo-lymphogenesis, on the atherosclerotic plaque’s 
progression and the stability-instability of the plaque.  
Through this investigation, we have also recognized the presence of myeloid-derived suppressor cells 
of the monocyte-macrophage line inside the atherosclerotic carotid plaque. These cells inside 
neoplasms have a dual function: trying to inhibit T lymphocytes activity from avoiding self-inflicted 
damage, although, at the same time, they facilitate neo-angiogenesis, and thus tumor’s growth and its 
dissemination.  
In atherosclerotic carotid plaques, these cells will probably inhibit T cells’ activity, as they do not 
localize near such cells, and they foster lymphogenesis more extensively that angiogenesis, given 
their localization close to lymphatic vessels and not near blood vessels.  
It will be beneficial to continue the study trying to identify the functions of myeloid-derived 
suppressor cells in particular, by pinpointing the cytokines that they produce, to understand that type 
of activity they possess inside the atherosclerotic plaque.   
Therefore, this investigation, regardless of the riveting and not yet identified data in the literature, it 
represents the preliminary phase of other possible examinations of atherosclerotic carotid plaques.  
The inspection of new plaques and additional markers will allow us to acquire significant results for 
an overall assessment of the plaque, and hopefully, to the identification of areas at a higher 
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